An Open Label Extension Study of Phase III Clinical Trial of Duloxetine in Patients With Fibromyalgia
Phase 3
- Conditions
- Fibromyalgia
- Registration Number
- JPRN-jRCT2080221803
- Lead Sponsor
- SHIONOGI & CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Participants who have completed the 15-week treatment in the preceding study (A Phase III clinical trial of duloxetine in participants with fibromyalgia), etc.
Exclusion Criteria
Participants with pain caused by diseases other than fibromyalgia and which possibly has any effect to the assessment, etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method